Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.50)
# 2,338
Out of 4,414 analysts
24
Total ratings
38.89%
Success rate
-8%
Average return
Main Sectors:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $12.60 | +296.83% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $25.60 | +95.31% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $91.77 | +0.25% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $25.58 | -21.81% | 1 | Mar 31, 2023 | |
| BNOX Bionomics | Upgrades: Outperform | $6 | $0.93 | +545.51% | 2 | Mar 10, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $139.83 | -7.03% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $16.81 | +197.44% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $16.42 | +52.25% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $22.77 | +229.38% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | n/a | $83.80 | - | 1 | Mar 1, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $937.61 | - | 1 | Feb 25, 2020 | |
| BLUE bluebird bio | Upgrades: Outperform | n/a | $0.90 | - | 1 | Feb 3, 2020 | |
| INCY Incyte | Assumes: Overweight | n/a | $53.09 | - | 2 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $12.60
Upside: +296.83%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $25.60
Upside: +95.31%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $91.77
Upside: +0.25%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $25.58
Upside: -21.81%
Bionomics
Mar 10, 2023
Upgrades: Outperform
Price Target: $6
Current: $0.93
Upside: +545.51%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $139.83
Upside: -7.03%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $16.81
Upside: +197.44%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $16.42
Upside: +52.25%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $22.77
Upside: +229.38%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: n/a
Current: $83.80
Upside: -
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $937.61
Upside: -
bluebird bio
Feb 3, 2020
Upgrades: Outperform
Price Target: n/a
Current: $0.90
Upside: -
Incyte
May 31, 2018
Assumes: Overweight
Price Target: n/a
Current: $53.09
Upside: -